Shares of Lupin dipped 5 per cent to Rs 859.50 on the BSE in Friday’s intra-day trade after the drugmaker reported lower-than-expected margins and net profit in December quarter (Q3FY22) due to one-time expenses related to residual metformin returns and provision for aged stock returns of Oseltamivir.